CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
Szu-Aun Lim(University of Cincinnati), Andrew M. Waters(University of North Carolina at Chapel Hill), Adrienne D. Cox(University of North Carolina at Chapel Hill), Wen-Hsuan Chang(University of North Carolina at Chapel Hill), Kenneth D. Greis(University of Cincinnati), Grace Goodhart(University of Cincinnati), Julien Dilly(Massachusetts Institute of Technology), Vidushi K. Trivedi(University of Cincinnati), Sarah E. Ackermann(University of North Carolina at Chapel Hill), R. J. Beal(University of Cincinnati), Craig M. Goodwin(University of North Carolina at Chapel Hill), Channing J. Der(University of North Carolina at Chapel Hill), G. Aaron Hobbs(Medical University of South Carolina), Kirsten L. Bryant(University of North Carolina at Chapel Hill), Andrew J. Aguirre(Broad Institute), M. Satyadi(University of Cincinnati), Amber M. Amparo(University of North Carolina at Chapel Hill), Syed A. Ahmad(University of Cincinnati), R Mukherjee, Haley Todd(University of Cincinnati), Rachel Bridgens(University of Cincinnati), A. Cole Edwards(University of North Carolina at Chapel Hill), Sara M. Shehadeh(University of Cincinnati), Clint A. Stalnecker(University of North Carolina at Chapel Hill)
Cited by 4
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
|Cancer Discovery|2016|632
Rho-family GTPases: it's not only Rac and Rho (and I like it)
|Journal of Cell Science|2004|594